GRDN Stock Forecast & Price Target

Guardian Pharmacy Services Inc. reported a robust revenue growth of 17.4% year-over-year, reaching $397.6 million, which surpassed both company estimates and consensus expectations. The company experienced a notable increase in its resident count, rising by 10% year-over-year to 205,000, alongside a 14% year-over-year growth in the number of prescriptions. Additionally, improvements in purchasing and reimbursement processes for vaccine administration are expected to enhance profitability and support continued operational efficiency gains, positioning the company well for future growth in 2026.

Guardian Pharmacy Services Inc. faces multiple fundamental challenges that contribute to a negative outlook on its stock, including significant regulatory risks stemming from upcoming drug price negotiations under the Inflation Reduction Act (IRA) and the inability to effectively manage acquired assets. Additionally, while management has raised its FY26 guidance, it anticipates only low double-digit normalized adjusted EBITDA growth, indicating limited revenue expansion despite the heightened guidance. Furthermore, the competitive landscape suggests that larger providers could overshadow Guardian through enhanced operational efficiencies, compounded by internal difficulties in hiring and retaining clinical staff as well as potential supply chain disruptions.